Disc Medicine, Inc.

NasdaqGM IRON

Disc Medicine, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024

Disc Medicine, Inc. Debt to Equity Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqGM: IRON

Disc Medicine, Inc.

CEO	Dr. John D. Quisel Esq., J.D., Ph.D.
IPO Date	Aug. 12, 2020
Location	United States
Headquarters	321 Arsenal Street
Employees	82
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Key trends

Past 5 years